Wayne A Ray, Cecilia P Chung, C Michael Stein, Walter Smalley, Eli Zimmerman, William D Dupont, Adriana M Hung, James R Daugherty, Alyson Dickson, Katherine T Murray
IMPORTANCE: Diltiazem, a commonly prescribed ventricular rate-control medication for patients with atrial fibrillation, inhibits apixaban and rivaroxaban elimination, possibly causing overanticoagulation. OBJECTIVE: To compare serious bleeding risk for new users of apixaban or rivaroxaban with atrial fibrillation treated with diltiazem or metoprolol. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included Medicare beneficiaries aged 65 years or older with atrial fibrillation who initiated apixaban or rivaroxaban use and also began treatment with diltiazem or metoprolol between January 1, 2012, and November 29, 2020...
April 15, 2024: JAMA